Flash BioSolutions obtains Pharmaceutical Establishment status, opening up new avenues for its revolutionary FlashRNA® technology
The company's recent achievement highlights their dedication to delivering high-quality innovative therapies. They are particularly proud of their revolutionary RNA technology, which has the potential to greatly impact the treatment of severe or genetic diseases and vaccines.
Toulouse, France, 5 March2024 - Flash BioSolutions, a biopharmaceutical development and manufacturing company (CDMO), is proud to announce that it has been certified Pharmaceutical Establishment status by the French National Agency for the Safety of Medicines (ANSM). This status recognises Flash BioSolutions' commitment to the highest manufacturing standards in the biomanufacturing of vectors for injectable pharmaceutical products.
This Pharmaceutical Establishment status provides Flash BioSolutions with additional regulatory authority and strengthens its ability to develop and deliver high quality products to its partners and customers. This step underlines Flash BioSolutions' commitment to innovation and excellence.
One of Flash BioSolutions' two flagship technologies, FlashRNA®, is a revolutionary RNA technology. Designed to be injected directly into humans, FlashRNA® opens up new perspectives in the treatment of genetic diseases, vaccines, cancers and other serious conditions. FlashRNA® technology promises to be an effective and innovative solution to major unmet medical needs.
« We are extremely proud to receive Pharmaceutical Establishment status » said CEO Jérôme Bédier. « This achievement demonstrates our commitment to excellence and reinforces our determination to deliver breakthrough therapies that could be game changers for our customers in the treatment of serious diseases. We look forward to working with our partners to realise the full potential of this FlashRNA® technology, which will be injected into humans as early as 2025. »
« We are convinced that this certification will reinforce our customers' confidence in our ability to provide high-quality biomanufacturing solutions » added Virginie Jassin, Quality Director. « We would like to thank all our employees for their investment. Their collaboration has been essential in reaching this important milestone in the life of the company. »
About Flash BioSolutions:
Created in 2005 and based at the Oncopole site in Toulouse, Flash BioSolutions is the commercial brand name of Flash Therapeutics, a CDMO specialising in the industrial production of DNA or RNA vectors for clients in gene and cell therapy and vaccines. Flash BioSolutions has a robust platform and manufacturing process enabling it to deliver high-purity, high-concentration viral vectors for the research, pre-clinical, clinical and commercial phases.
Medias contact:
Head of communication – Soraya Sandokchi
soraya.sandokchi@flashtherapeutics.com
+33 (0) 5 82 95 55 46
Download the Press Release :
English version